Regional changes in type 1 cannabinoid receptor availability in Parkinson's disease in vivo

Neurobiology of Aging

Volumn 33, Issue 3, 2012, Pages 620.e1-620.e8

  Van Laere, Koen ^a   Casteels, Cindy ^a   Lunskens, Sophie ^a   Goffin, Karolien ^a   Grachev, Igor D ^b   Bormans, Guy ^c   Vandenberghe, Wim ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b MERCK RESEARCH LABORATORIES   (United States)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

CB1 receptor; Endocannabinoid system; Levodopa induced dyskinesia; Parkinson's disease; PET

Indexed keywords

CANNABINOID 1 RECEPTOR; ENTACAPONE; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; RADIOLIGAND; ROPINIROLE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DISEASE SEVERITY; DYSKINESIA; FEMALE; HUMAN; IN VIVO STUDY; LEVODOPA INDUCED DYSKINESIA; LIMBIC CORTEX; MALE; NIGRONEOSTRIATAL SYSTEM; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUBSTANTIA NIGRA; SYNAPTIC TRANSMISSION; UNIFIED PARKINSON DISEASE RATING SCALE;

EID: 84855806335     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2011.02.009     Document Type: Article

References (44)

1. Benarroch E. Endocannabinoids in basal ganglia circuits: implications for Parkinson disease. Neurology 2007, 69:306-309.
2. Berrendero F., Sepe N., Ramos J.A., Di Marzo V., Fernandez-Ruiz J.J. Analysis of cannabinoid receptor binding and mRNA expression and endogenous cannabinoid contents in the developing rat brain during late gestation and early postnatal period. Synapse 1999, 33:181-191.
3. Bisogno T., Berrendero F., Ambrosino G., Cebeira M., Ramos J.A., Fernandez-Ruiz J.J., Di Marzo V. Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function. Biochem. Biophys. Res. Commun 1999, 256:377-380.
4. Briggs G.G., Nebes R.D. Patterns of hand preference in a student population. Cortex 1975, 11:230-238.
5. Brotchie J.M. CB1 cannabinoid receptor signalling in Parkinson's disease. Curr. Opin. Pharmacol 2003, 3:54-61.
6. Burns H.D., Van Laere K., Sanabria-Bohorquez S., Hamill T.G., Bormans G., Eng W.S., Gibson R., Ryan C., Connolly B., Patel S., Krause S., Vanko A., Van Hecken A., Dupont P., De Lepeleire I., Rothenberg P., Stoch S.A., Cote J., Hagmann W.K., Jewell J.P., Lin L.S., Liu P., Goulet M.T., Gottesdiener K., Wagner J.A., de Hoon J., Mortelmans L., Fong T.M., Hargreaves R.J. [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proc. Natl. Acad. Sci. U. S. A 2007, 104:9800-9805.
7. Carroll C.B., Bain P.G., Teare L., Liu X., Joint C., Wroath C., Parkin S.G., Fox P., Wright D., Hobart J., Zajicek J.P. Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology 2004, 63:1245-1250.
8. Casteels C., Vanbilloen B., Vercammen D., Bosier B., Lambert D.M., Bormans G., Van Laere K. Influence of chronic bromocriptine and levodopa administration on cerebral type 1 cannabinoid receptor binding. Synapse 2010, 64:617-623.
9. Di Marzo V., Matias I. Endocannabinoid control of food intake and energy balance. Nat. Neurosci 2005, 8:585-589.
10. Fabbrini G., Brotchie J.M., Grandas F., Nomoto M., Goetz C.G. Levodopa-induced dyskinesias. Mov. Disord 2007, 22:1379-1389.
11. Fox S.H., Brotchie J.M., Lang A.E. Non-dopaminergic treatments in development for Parkinson's disease. Lancet Neurol 2008, 7:927-938.
12. Fox S.H., Henry B., Hill M., Crossman A., Brotchie J. Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov. Disord 2002, 17:1180-1187.
13. Garcia-Arencibia M., Garcia C., Kurz A., Rodriguez-Navarro J.A., Gispert-Sachez S., Mena M.A., Auburger G., de Yebenes J.G., Fernandez-Ruiz J. Cannabinoid CB1 receptors are early downregulated followed by a further upregulation in the basal ganglia of mice with deletion of specific park genes. J. Neural Transm. Suppl. 2009, 269-275.
14. Guy W. ECDEU Assessment Manual for Psychopharmacology 1976, US Department of Health, Eduation and Welfare, Rockville, MD.
15. Haznedar M.M., Buchsbaum M.S., Hazlett E.A., Licalzi E.M., Cartwright C., Hollander E. Volumetric analysis and three-dimensional glucose metabolic mapping of the striatum and thalamus in patients with autism spectrum disorders. Am. J. Psychiatry 2006, 163:1252-1263.
16. Herkenham M., Lynn A.B., De Costa B.R., Richfield E.K. Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res 1991, 547:267-274.
17. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., De Costa B.R., Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci 1991, 11:563-583.
18. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., De Costa B.R., Rice K.C. Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. U. S. A 1990, 87:1932-1936.
19. Hirsch E., Graybiel A.M., Agid Y.A. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 1988, 334:345-348.
20. Hurley M.J., Mash D.C., Jenner P. Expression of cannabinoid CB1 receptor mRNA in basal ganglia of normal and parkinsonian human brain. J. Neural Transm 2003, 110:1279-1288.
21. Katona I., Freund T.F. Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat. Med 2008, 14:923-930.
22. Kreitzer A.C., Malenka R.C. Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature 2007, 445:643-647.
23. Lastres-Becker I., Cebeira M., De Ceballos M.L., Zeng B.Y., Jenner P., Ramos J.A., Fernandez-Ruiz J.J. Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets. Eur. J. Neurosci 2001, 14:1827-1832.
24. Mailleux P., Vanderhaeghen J.J. Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience 1992, 48:655-668.
25. Matyas F., Yanovsky Y., Mackie K., Kelsch W., Misgeld U., Freund T.F. Subcellular localization of type 1 cannabinoid receptors in the rat basal ganglia. Neuroscience 2006, 137:337-361.
26. Ouchi Y., Yoshikawa E., Sekine Y., Futatsubashi M., Kanno T., Ogusu T., Torizuka T. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann. Neurol 2005, 57:168-175.
27. Piomelli D. The molecular logic of endocannabinoid signalling. Nat. Rev. Neurosci 2003, 4:873-884.
28. Pisani V., Moschella V., Bari M., Fezza F., Galati S., Bernardi G., Stanzione P., Pisani A., Maccarrone M. Dynamic changes of anandamide in the cerebrospinal fluid of Parkinson's disease patients. Mov. Disord 2010, 25:920-924.
29. Quarantelli M., Berkouk K., Prinster A., Landeau B., Svarer C., Balkay L., Alfano B., Brunetti A., Baron J.C., Salvatore M. Integrated software for the analysis of brain PET/SPECT studies with partial-volume-effect correction. J. Nucl. Med 2004, 45:192-201.
30. Robbe D., Alonso G., Duchamp F., Bockaert J., Manzoni O.J. Localization and mechanisms of action of cannabinoid receptors at the glutamatergic synapses of the mouse nucleus accumbens. J. Neurosci 2001, 21:109-116.
31. Sanabria-Bohorquez S., Hamill T., Goffin K., De Lepeleire I., Bormans G., Burns H.D., Van Laere K. Kinetic analysis of the cannabinoid-1 receptor PET tracer [(18)F]MK-9470 in human brain. Eur. J. Nucl. Med. Mol. Imaging 2010, 37:920-933.
32. Sieradzan K.A., Fox S.H., Hill M., Dick J.P., Crossman A.R., Brotchie J.M. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology 2001, 57:2108-2111.
33. Silverdale M.A., McGuire S., McInnes A., Crossman A.R., Brotchie J.M. Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease. Exp. Neurol 2001, 169:400-406.
34. Stella N. Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia 2010, 58:1017-1030.
35. Terry G., Liow J.S., Chernet E., Zoghbi S.S., Phebus L., Felder C.C., Tauscher J., Schaus J.M., Pike V.W., Halldin C., Innis R.B. Positron emission tomography imaging using an inverse agonist radioligand to assess cannabinoid CB1 receptors in rodents. Neuroimage 2008, 41:690-698.
36. Thie J.A., Hubner K.F., Isidoro F.P., Smith G.T. A weight index for the standardized uptake value in 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography. Mol. Imaging Biol 2007, 9:91-98.
37. Uchigashima M., Narushima M., Fukaya M., Katona I., Kano M., Watanabe M. Subcellular arrangement of molecules for 2-arachidonoyl-glycerol-mediated retrograde signaling and its physiological contribution to synaptic modulation in the striatum. J. Neurosci 2007, 27:3663-3676.
38. van der Stelt M., Di Marzo V. The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. Eur. J. Pharmacol 2003, 480:133-150.
39. Van Laere K., Casteels C., Dhollander I., Goffin K., Grachev I., Bormans G., Vandenberghe W. Widespread decrease of type 1 cannabinoid receptor availability in Huntington disease in vivo. J. Nucl. Med 2010, 51:1413-1417.
40. Van Laere K., Goffin K., Bormans G., Casteels C., Mortelmans L., de Hoon J., Grachev I., Vandenbulcke M., Pieters G. Relationship of type 1 cannabinoid receptor availability in the human brain to novelty-seeking temperament. Arch. Gen. Psychiatry 2009, 66:196-204.
41. Van Laere K., Goffin K., Casteels C., Dupont P., Mortelmans L., de Hoon J., Bormans G. Gender-dependent increases with healthy aging of the human cerebral cannabinoid-type 1 receptor binding using [(18)F]MK-9470 PET. Neuroimage 2008, 39:1533-1541.
42. Walsh S., Mnich K., Mackie K., Gorman A.M., Finn D.P., Dowd E. Loss of cannabinoid CB1 receptor expression in the 6-hydroxydopamine-induced nigrostriatal terminal lesion model of Parkinson's disease in the rat. Brain Res. Bull 2010, 81:543-548.
43. Wilson R.I., Nicoll R.A. Endocannabinoid signaling in the brain. Science 2002, 296:678-682.
44. Yin H.H., Lovinger D.M. Frequency-specific and D2 receptor-mediated inhibition of glutamate release by retrograde endocannabinoid signaling. Proc. Natl. Acad. Sci. U. S. A 2006, 103:8251-8256.